Biomarkers for cardiodiabetes

1. A method of treating cardiodiabetes in a normoglycemic subject comprising:

(a) measuring the concentration of a biomarker panel in a sample from the subject, the biomarker panel consisting of adiponectin, high sensitivity C-reactive protein (hsCRP) and intact proinsulin; and

(b) determining a risk level associated with each biomarker,

wherein an adiponectin concentration of >10 mg/L, 7-10 mg/L and <7 mg/L indicates a low, medium and high risk level, respectively, for adiponectin;

an hsCRP concentration of 0-1 mg/L, >1-3 mg/L and >3-10 mg/L indicates a low, medium and high risk level, respectively, for hsCRP; and

an intact proinsulin concentration of ≦11 pmol/L and >11 pmol/L indicates a low and high risk level, respectively, for intact proinsulin;

(c) comparing the concentrations to each of the risk levels; and

(d) effecting a therapy with respect to the subject, wherein in the therapy is based on a combination of the risk levels.

2. The method of claim 1 wherein if the risk level associated with each of the concentrations of adiponectin, hsCRP and intact proinsulin respectively is selected from (a) high, high and high; (b) high, medium and high; (c) medium, high and high; (d) low, high and high; (e) low, medium and high; and (f) low, low and high, then the subject is administered a glitazone and a drug or combination of drugs selected from a glucagon-like peptide 1 (GLP-1) analog and an insulin.

3. The method of claim 1 wherein if the risk level associated with each of the concentrations of adiponectin, hsCRP and intact proinsulin respectively is selected from (a) high, low and high; (b) medium, medium and high; and (c) medium, low and high, then the subject is administered a glitazone and a drug or combination of drugs selected from a GLP-1 analog, an insulin and a dipeptidyl peptidase IV (DPPIV) inhibitor.

4. The method of claim 1 if the risk level associated with each of the concentrations of adiponectin, hsCRP and intact proinsulin respectively is selected from (a) high, high and low; (b) medium, high and low; (c) low, high and low; (d) low, medium and low; and (e) low, low and low, then the subject is administered metformin and a drug or combination of drugs selected from a glitazone, a GLP-1 analog, a DPPIV inhibitor and an insulin.

5. The method of claim 1 wherein if the risk level associated with each of the concentrations of adiponectin, hsCRP and intact proinsulin respectively is selected from (a) high, medium and low; (b) high, low and low; (c) medium, medium and low; and (d) medium, low and low, then the therapy comprises administering metformin and a drug or combination of drugs selected from a glitazone, a DPPIV inhibitor and an insulin.

6. The method of any of claims 1 - 4 wherein the subject is not administered a drug or combination of drugs selected from a sulfonylurea and a glinide.

7. The method of any of claims 1 - 5 wherein the subject is administered one or more additional drugs comprising one or more glucose lowering drugs.

8. The method of claim 1 wherein the sample comprises blood.

9. The method of claim 1 further comprising taking a measurement of at least one additional biomarker.

10. The method of claim 9 wherein the additional biomarker is selected from the group consisting of leptin, mRNAx, NFκB, IL-6, MMP-9, TNFα, eNOS, PPARγ, MCP-1, PAI-1, ICAM/VCAM, E-selectin, P-selectin, von Willebrand factor, sCD40L, insulin, glucose, HbA1c, free fatty acids, triglycerides, VLDL, small dense LDL, oxidized LDL, resistin, HDL, NO, IκB-α, IκB-β, p105, RelA, TNFα, MIF, inflammatory cytokines and molecules involved in signaling pathways.

11. The method of claim 10 wherein the additional biomarker is MMP-9.

12. The method of claim 11 wherein the concentration of intact proinsulin, hsCRP and adiponectin in the sample is measured and each is a high risk concentration.

13. The method of claim 10 wherein the additional biomarker is leptin.

14. The method of claim 1 further comprising:

contacting the sample from the subject with the a composition comprising a solid support comprising:

(a) a capture binding ligand selective for adiponectin,

(b) a capture binding ligand selective for hsCRP, and

(c) a capture binding ligand selective for intact proinsulin.